BioSpace News Archive

Palisade Bio, Inc. announced a 1-for-15 reverse split of its common stock, par value $0.01, effective at 5:00 PM ET on Friday April 5, 2024.

Affinity Biosensors, a leading innovator in the field of healthcare diagnostics, announces that its groundbreaking LifeScale AST system has received FDA clearance.

Neurosterix, a biopharmaceutical company dedicated to the development of allosteric modulator therapeutics for underserved neurological disorders, launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures.

CancerVax, Inc., developer of a breakthrough Universal Cancer Vaccine treatment that will use the body’s immune system to fight cancer, announced that its Reg A+ offering has been qualified by the SEC allowing the Company to formally launch a funding round of up to $5 million.

Molecure S.A., a biotechnology company that discovers and develops drugs to the clinical stage and leverages its globally unique expertise in medicinal chemistry and biology to explore and develop first-in-class small-molecule drugs that directly modulate protein activity and mRNA function to treat a range of incurable diseases, has published its 2023 annual report.

Kurin, Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced record revenues for the first quarter of 2024, following a record 2023.

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, announced the closing of a $132 million Series B financing.

Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M.

ADC Therapeutics SA announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from 4:00 to 5:30 p.m. EDT.

Helius Medical Technologies, Inc. announced it has partnered with Lovell Government Services, an SBA-certified Service Disabled Veteran Owned Small Business, to make the Company’s Portable Neuromodulation Stimulator device available to federal healthcare systems.